Mabel Mardones, Breast Medical OncologistPartner at Rocky Mountain Cancer , shared Paolo Tarantino’s, Clinical Research Fellow at Dana-Farber Cancer Institute and Visiting Professor at McGill University, post on X, adding:
“Great work! Completely agree that TdM1 is still alive and well for the right patients which are many. This is important to underscore for physicians and patients. AE profiles are very different. TdXd for the right patient as per DB05.”
Quoting Paolo Tarantino’s post:
“Adjuvant T-DXd is approved for pts with HER2+ BC and high-risk RD by DB05 criteria.
What about pts with lower risk RD?
We looked at approximately 10.000 patients in Flatiron, finding that 52% have low-risk RD, with 3yr DRFS 94%, suggesting that T-DM1 remains an adequate SoC for them. ASCO 2026 – Ab545”
Other articles featuring Mabel Mardones and Paolo Tarantino on OncoDaily.
